HealthQuill Blood Cancer
Johnson & Johnson has submitted regulatory applications to the US drug regulator and European Medicines Agency (EMA) for the extended approval of a blood cancer therapy.
Drugs Health Pharma

J&J seeks approval for its blood cancer therapy in US, European Union

Johnson & Johnson has submitted regulatory applications to the US drug regulator and European Medicines Agency (EMA) for the extended approval of a blood.

Read More
British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug regulator.
Drugs Health Pharma

AstraZeneca’s experimental blood cancer drug gets US priority review

British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug.

Read More
The US regulatory body has rejected Regeneron Pharmaceuticals, Inc.,’s blood cancer drug as it did not meet the pre-approval standards of the agency.
Drugs Health Pharma

US drug regulator blocks Regeneron’s blood cancer therapy 

The US regulatory body has rejected Regeneron Pharmaceuticals, Inc.,’s blood cancer drug as it did not meet the pre-approval standards of the agency.

Read More
Citius Pharmaceuticals, Inc., a US-based biotechnology company, got a green light from the country’s drug regulator for its immunotherapy treatment for a rare form of blood cancer that affects the skin.
Drugs Health Pharma

Citius’s blood cancer drug gets US regulatory body’s clearance 

Citius Pharmaceuticals, Inc., a US-based biotechnology company, got a green light from the country’s drug regulator for its immunotherapy treatment for a rare.

Read More
The US Food and Drug Administration has approved the Darzalex Faspro combination drug therapy of Janssen Research and Development for treating blood cancer.
Drugs Health Pharma

USFDA gives nod to Janssen Research’s blood cancer therapy 

The US Food and Drug Administration has approved the Darzalex Faspro combination drug therapy of Janssen Research and Development for treating blood cancer.

Read More
blood thinners
Drugs Health Medical

Strategy of genetic shielding of blood cells helps eradicate blood cancer

HQ Team July 18, 2024: In a reversal strategy in the war against cancer, researchers are now aiming to genetically cloak healthy cells.

Read More
Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to a statement.
Drugs Health Pharma

Pfizer’s blood cancer trial data shows survival of more than 2 years 

Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to.

Read More
https://www.cancer.gov/news-events/press-releases/2024/genetic-factors-predict-x-chromosome-loss
Drugs Health Pharma

Genetic factors may help predict loss of X chromosome in older women

Researchers co-led by the US-based National Cancer Institute have found genetic variants in women that may play a role in promoting abnormal blood.

Read More
British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a standard-of-care combination, according to the company.
Drugs Health Pharma

GSK’s blood cancer test drug halves risk of disease progression: Data 

British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a.

Read More
Johnson & Johnson announced that USFDA had approved a bi-weekly dose of its blood cancer therapy Tecvayli.
Drugs Health Pharma

Johnson & Johnson’s blood cancer medicine cleared for bi-weekly use

HQ Team February 21, 2024: Johnson & Johnson announced that USFDA had approved a bi-weekly dose of its blood cancer therapy Tecvayli. The regulatory.

Read More